Patritumab deruxtecan would not enhance OS vs chemotherapy in EGFR+ superior/metastatic NSCLC: © inventory.adobe.com.
Amongst sufferers with EGFR mutation–optimistic regionally superior or metastatic non–small cell lung most cancers (NSCLC), patritumab deruxtecan (HER3-DXd) remedy didn’t enhance total survival outcomes in contrast with platinum-based chemotherapy remedy, in line with information from the part 3 HERTHENA-Lung02 examine which had been shared on the 2025 ASCO Annual Assembly.
The median total survival was 16.0 months within the patritumab deruxtecan arm versus 15.9 months within the chemotherapy arm. The median follow-up was 18.7 versus 18.6 months within the two arms, respectively.
Primarily based on these total survival information, Merck beforehand withdrew its biologics license software in search of FDA approval of patritumab deruxtecan to be used on this setting.
Further Efficacy Knowledge
Beforehand reported outcomes from the first evaluation of the HERTHENA-Lung02 trial confirmed that patritumab deruxtecan considerably diminished the chance of illness development or dying versus chemotherapy. The median progression-free survival was 5.8 months with patritumab deruxtecan versus 5.4 months with chemotherapy. The nine-month likelihood of progression-free survival was 29% versus 19%, respectively. The progression-free survival profit was sustained throughout most subgroups, together with these outlined by age, intercourse, geographic area, mind metastases at baseline, smoking standing and ECOG efficiency rating.
The confirmed goal response price was 35.2% with patritumab deruxtecan versus 25.3% with chemotherapy. The illness management price was 80.5% with patritumab deruxtecan versus 75.8% with chemotherapy. The median time to response was 1.5 months in every arm and the median period of response was about 5.5 months in each arms.
Intracranial efficacy was evaluated in 105 and 95 sufferers within the remedy and management arms, respectively. The median intracranial response was 5.4 versus 4.2 months, respectively. The confirmed intracranial goal response price was 19.0% and 11.6% within the two arms, respectively. The intracranial full response price was 12.4% versus 4.2% and the intracranial illness management price was 68.6% and 61.1%, respectively. The median intracranial time to response and median intracranial period of response had been 2.1 versus 2.6 months and 4.5 versus 4.2 months, respectively.
The security evaluable inhabitants included 290 and 280 sufferers within the patritumab deruxtecan and chemotherapy arms, respectively. The investigators thought-about the toxicities to be usually manageable and just like prior analysis with the examine remedies. Grade 3 (extreme) or larger treatment-related uncomfortable side effects occurred in 57.9% versus 46.1% of the remedy and management arms, respectively. Critical treatment-related uncomfortable side effects had been reported for 22.4% versus 12.5% of the 2 arms, respectively. There have been 4 treatment-related aspect effect-linked deaths within the patritumab deruxtecan arm in contrast with one within the chemotherapy arm. Of be aware, the incidence of adjudicated interstitial lung illness was 5.2% for the patritumab deruxtecan arm.
HERTHENA-Lung02 Design and Affected person Traits
The open-label part 3 HERTHENA-Lung02 trial enrolled sufferers with regionally superior or metastatic NSCLC harboring an EGFR mutation. Sufferers needed to have illness development after obtained one or two prior strains of an U.S. Meals and Drug-approved EGFR TKI, together with a third-generation TKI.
Affected person traits had been effectively balanced between the patritumab deruxtecan (n = 293) and chemotherapy (293 sufferers) arms. The median age throughout each arms was 64 years (vary, 34-86), about 60% of sufferers had been feminine, and about 60% of sufferers had been Asian. Just below two-thirds of sufferers had been never-smokers, and the median time since preliminary analysis was 24.2 months (vary, 2.5-146.1). About two-thirds of sufferers had an ECOG efficiency rating of 1, with the rest having an ECOG efficiency rating of zero. About 44% of sufferers had a historical past of mind metastasis, with about one-third having mind metastases at baseline.
The approximate breakdown of EGFR activating mutations was 60% with Ex19del, 39% with L858R, and 1% with twin Ex19del and L858R. Relating to prior EGFR TKIs, three-fourths of sufferers had beforehand obtained solely third-generation EGFR TKIs, whereas one-fourth had obtained each third- and first/second-generation TKIs. Over 90% of sufferers had prior Tagrisso (osimertinib).
Sufferers obtained patritumab deruxtecan at 5.6 mg/kg (IV) each three weeks or platinum-based chemotherapy. Chemotherapy consisted of 4 cycles of pemetrexed plus both cisplatin or carboplatin, adopted by non-compulsory upkeep pemetrexed in sufferers whose illness didn’t progress after the preliminary 4 mixture cycles.
Development-free survival per blinded unbiased central overview was the first finish level, with secondary finish factors consisting of total survival, investigator-assessed progression-free survival, goal response price, period of response, scientific profit price, illness management price, time to response, intracranial progression-free survival, high quality of life and security.
Relating to subsequent steps, examine investigators stated, “Analysis of the affiliation of biomarkers, together with HER3 IHC, with efficacy parameters in HERTHENA-Lung02 and their suitability as a predictive biomarker is ongoing.”
Reference
Mok T, Yu H, Lim SM, Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) superior non-small cell lung most cancers (NSCLC) after a third-generation EGFR TKI: The part 3 HERTHENA-Lung02 examine. J Clin Oncol. 2025;43(suppl 17):8506. doi: 10.1200/JCO.2025.43.16_suppl.8506
